Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof
AssigneeCelera Corporation
InventorsMichele CARGILL, Ann B. BEGOVICH, Victoria CARLTON, Steven J. SCHRODI, Heather C. ALEXANDER
Life of this patent
Estimating the term…
Abstract
The present invention is based on the discovery of genetic polymorphisms that are associated with rheumatoid arthritis. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
Claims20
A method of determining whether a human has an increased risk for developing rheumatoid arthritis, comprising testing nucleic acid from said human for the presence or absence of a polymorphism in said human's nucleic acid, wherein said polymorphism is at position 101 of any of SEQ ID NOS:10,916-49,582 and 50,231, and correlating the presence or absence of said polymorphism with said human having an increased risk for developing rheumatoid arthritis.
A method of determining whether a human has an increased risk for developing rheumatoid arthritis, comprising testing nucleic acid from said human for the presence or absence of an LD polymorphism in said human's nucleic acid, wherein said LD polymorphism is in linkage disequilibrium with a polymorphism at position 101 of any of SEQ ID NOS:10,916-49,582 and 50,231, and correlating the presence or absence of said LD polymorphism with said human having an increased risk for developing rheumatoid arthritis.
An isolated polynucleotide which specifically hybridizes to a segment of a nucleic acid molecule, wherein said segment includes a polymorphism at position 101 of any of SEQ ID NOS:10,916-49,582 and 50,231.
A method for conducting a clinical trial in which a therapeutic agent is evaluated in at least one human, the method comprising testing nucleic acid from said human for the presence or absence of a polymorphism in said human's nucleic acid, wherein said polymorphism is at position 101 of any of SEQ ID NOS:10,916-49,582 and 50,231, and determining whether to include or exclude said human in said clinical trial based on said genotype.
Dependencies are inferred from the claim text.